Startups
Kynos Therapeutics
Developed inhibitors of kynurenine 3-monooxygenase to treat inflammation, including the investigational KNS366 program for acute pancreatitis. Dr. Falk Pharma acquired and integrated the University of Edinburgh spinout in October 2024; its scientific founders remained consultants to the acquirer.
Founded 2022